Computational Exploration of Fluorocyclopentenyl‐purines and‐pyrimidines Derivatives as Potential Inhibitors of Epidermal Growth Factor Receptor (EGFR) for the Treatment of Breast Cancer
Chemistry & Biodiversity · 2023
DOI: 10.1002/cbdv.202301190 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemistry & Biodiversity, 2023. Verfasst von Syeda Abida Ejaz und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, Faculty of Pharmacv, The Islamia University of, Bahawalpur, 63100, Pakistan. Hauptthemen laut MEDLINE: Breast Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 57 Literaturangaben. Gefördert von: Deputyship for Research and Innovation, Ministry of Education.
Abstract (Originalsprache)
The Epidermal Growth Factor Receptor (EGFR) is an important therapeutic target for the treatment of a variety of epithelial malignancies, including breast cancer, in which EGFR is aberrantly expressed.The fluorocyclopentenyl‐purine‐pyrimidines derivatives, which have previously been described as powerful compounds against breast cancer, were selected to investigate their potential against EGFR using computational tools in an effort to obtain potent inhibitors with fewer adverse effects. The molecule's chemical reactivity and stability were assessed by determining the HOMO‐LUMO energy gap using density functional theory (DFT) calculations. Among all the selected compounds, PU4 displayed a HOMO‐LUMO gap of 0.191 eV. Additionally, molecular docking analysis was performed to assess the binding affinities of PU4 within the active pocket of EGFR‐TK. The compound PU4 showed potent interactions with EGFR exhibiting −32.3 kJ/mol binding energy which was found best as compared to gefitinib i. e., −27.4 kJ/mol which was further validated by molecular dynamics simulations and ADMET analysis. The results of these analyses indicate that the top hits obtained from the virtual screening possess the ability to act as effective EGFR inhibitor. Therefore, it is recommended to further investigate the inhibitory potential of these identified compounds using in vitro and in vivo approaches.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Chemistry, Faculty of Pharmacv, The Islamia University of, Bahawalpur, 63100, Pakistan.
- Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh, 11451, Saudi Arabia.
- Department of Biochemistry, College of Science, King Saud University, P.O. Box, 22452, Riyadh 11451, Saudi Arabia.
- Bahawalpur College of Pharmacy, Bahawalpur Medical and Dental College, Bahawalpur, Pakistan.
- Department of Pharmacy, Royal Institute of Medical Sciences (RIMS) Multan 60000, Pakistan.
- Department of Chemistry and Biochemistry, Texas Tech University, Lubbock, TX, 79409-1061, USA.
ORCID-Profile: Syeda Abida Ejaz
Förderung
- Deputyship for Research and Innovation, Ministry of Education
Zitieren
APA
Abida Ejaz, S., Sajjad Bilal, M., Aziz, M., Wani, T. A., Zargar, S., Fayyaz, A., Hassan, S., Ahmed, A., Al Kahtani, H. M., & Siddique, F. (2023). Computational Exploration of Fluorocyclopentenyl‐purines and‐pyrimidines Derivatives as Potential Inhibitors of Epidermal Growth Factor Receptor (EGFR) for the Treatment of Breast Cancer. Chemistry & Biodiversity. https://doi.org/10.1002/cbdv.202301190
Vancouver
Abida Ejaz S, Sajjad Bilal M, Aziz M, Wani TA, Zargar S, Fayyaz A, et al. Computational Exploration of Fluorocyclopentenyl‐purines and‐pyrimidines Derivatives as Potential Inhibitors of Epidermal Growth Factor Receptor (EGFR) for the Treatment of Breast Cancer. Chemistry & Biodiversity. 2023. doi:10.1002/cbdv.202301190
BibTeX
@article{AbidaEjaz2023,
author = {Abida Ejaz, Syeda and Sajjad Bilal, Muhammad and Aziz, Mubashir and Wani, Tanveer A and Zargar, Seema and Fayyaz, Ammara and Hassan, Sidra and Ahmed, Aftab and Al Kahtani, Hammad M and Siddique, Farhan},
title = {Computational Exploration of Fluorocyclopentenyl‐purines and‐pyrimidines Derivatives as Potential Inhibitors of Epidermal Growth Factor Receptor (EGFR) for the Treatment of Breast Cancer},
journal = {Chemistry & Biodiversity},
year = {2023},
doi = {10.1002/cbdv.202301190}
}
EUVIMED